AG-126 (Tyrphostin AG-126): Selective ERK1/2 Inhibitor Profile

Executive Summary: AG-126 (Tyrphostin AG-126) is a potent, selective inhibitor of ERK1 (p44) and ERK2 (p42) phosphorylation, with an IC₅₀ range of 25–50 μM in cell-based assays (APExBIO product page). In vitro, it robustly blocks MAPK/ERK pathway activation and PCW-evoked cytokine release, but is less effective against LPS-triggered responses (AG-126: ERK1/2 Inhibition for Neuroinflammatory Models). In vivo, AG-126 reduces leukocyte infiltration and intracranial pressure in rat models of pneumococcal cell wall-induced meningitis, without altering key physiological parameters. The crystalline solid is soluble up to 10 mg/ml in DMSO and requires -20°C storage. AG-126 is intended for research use only; no clinical trials have been reported (APExBIO).

Biological Rationale

The MAPK/ERK pathway orchestrates key cellular processes including proliferation, differentiation, and inflammatory cytokine release (AG-126: ERK1/2 Inhibition for Neuroinflammatory Models). Dysregulation of ERK1/2 activity is implicated in neuroinflammation and neurodevelopmental disorders. Selective inhibition of ERK phosphorylation allows researchers to dissect intracellular signaling events critical for models of inflammation and repetitive behaviors. AG-126 provides a tool for targeting this pathway with precise selectivity and documented efficacy in both in vitro and in vivo systems.

Mechanism of Action of AG-126 (Tyrphostin AG-126)

AG-126, a 2-[(3-hydroxy-4-nitrophenyl)methylene]-propanedinitrile derivative, acts as a selective inhibitor of ERK1 (p44) and ERK2 (p42) by blocking their phosphorylation. The compound’s IC₅₀ for ERK1/2 inhibition lies in the 25–50 μM range, as established in cell-based phosphorylation assays (product information). By preventing ERK1/2 activation, AG-126 modulates downstream transcriptional and post-translational events in the MAPK/ERK cascade. It attenuates the release of pro-inflammatory cytokines in response to pneumococcal cell wall (PCW) stimulation but is comparatively less effective against LPS-induced cytokine responses. The selective inhibition profile enables fine-grained analysis of ERK-dependent versus ERK-independent signaling events (AG-126: Optimizing ERK1/2 Inhibition Workflows).

Evidence & Benchmarks

• AG-126 inhibits ERK1/2 phosphorylation in vitro with an IC₅₀ between 25–50 μM, as shown by immunoblot and kinase assays (APExBIO).
• In rat models of pneumococcal cell wall-induced meningitis, AG-126 reduces leukocyte infiltration into cerebrospinal fluid and lowers intracranial pressure, without adversely affecting arterial blood pressure or blood gases (product information).
• AG-126 selectively suppresses PCW-evoked but not LPS-induced cytokine release in vitro, indicating pathway specificity (AG-126: ERK1/2 Inhibition for Neuroinflammatory Models).
• The compound is soluble up to 10 mg/ml in DMSO and dimethyl formamide, with limited solubility in ethanol (≤0.15 mg/ml), and should be stored at -20°C for stability (APExBIO).
• No clinical trials in humans have been reported; AG-126 is for research use only (APExBIO).

This article extends prior coverage from AG-126: Optimizing ERK1/2 Inhibition Workflows by providing quantitative in vivo efficacy benchmarks and clarifying solubility/storage conditions. It also builds on AG-126: ERK1/2 Inhibition for Neuroinflammatory Models by linking selective ERK inhibition to disease-relevant cytokine response profiles.

Applications, Limits & Misconceptions

AG-126 is widely used for:

• In vitro inhibition of ERK1/2 phosphorylation for mechanistic studies of the MAPK/ERK pathway.
• Modeling selective cytokine release inhibition in neuroinflammatory and immune cell assays.
• In vivo modulation of ERK pathway activity in rodent neuroinflammation and meningitis models (APExBIO).

However, its specificity for PCW-evoked over LPS-induced cytokine responses should be considered when interpreting results (AG-126: ERK1/2 Inhibition for Neuroinflammatory Models).

Common Pitfalls or Misconceptions

• AG-126 is not a pan-cytokine inhibitor; its efficacy is pathway- and stimulus-dependent.
• It should not be used in clinical or diagnostic settings; it is strictly for research use.
• Long-term storage of solutions is discouraged; freshly prepared solutions are recommended for each experiment (APExBIO).
• Solubility is highly solvent-dependent; do not exceed recommended concentrations in ethanol or aqueous buffers.
• AG-126 does not directly inhibit upstream kinases or unrelated signaling pathways.

Workflow Integration & Parameters

Protocol Parameters

• Compound preparation: Dissolve AG-126 up to 10 mg/ml in DMSO or dimethyl formamide; if using ethanol, do not exceed 0.15 mg/ml (product information).
• In vitro ERK inhibition: Typical working concentration is 25–50 μM for selective ERK1/2 phosphorylation inhibition; optimize based on cell type and assay sensitivity (AG-126: ERK1/2 Inhibition for Neuroinflammatory Models).
• In vivo dosing: Refer to published neuroinflammation models for species- and route-specific dosing regimens; monitor physiological parameters such as arterial blood pressure and blood gases for off-target effects.
• Storage: Store AG-126 powder at -20°C, protected from light; ship with blue ice. Use freshly prepared solutions (APExBIO).

Conclusion & Outlook

AG-126 (Tyrphostin AG-126) is a validated, selective ERK1/2 phosphorylation inhibitor suitable for dissecting MAPK/ERK signaling in both in vitro and in vivo models. Its specificity enables clear attribution of phenotypic outcomes to ERK pathway modulation, as evidenced in neuroinflammatory and cytokine release studies. While no human clinical data exist, AG-126 remains a valuable research reagent for advancing understanding of ERK-dependent processes. For future work, refining dosing strategies and exploring combinatorial pathway inhibition may further enhance the utility of AG-126 in preclinical research (APExBIO).